IRLAB Therapeutics
31.12.2021 10:51:35 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK Tes Ireland Achieves ISO Certification Milestone and Recognized in National Digital Infrastructure Report4.6.2026 15:00:00 CEST | Press release
DUBLIN, IE / ACCESS Newswire / June 4, 2026 / SK tes, a global leader in sustainable technology lifecycle services, today announced that its Ireland facility has successfully passed audits for ISO 9001 (Quality Management), ISO 14001 (Environmental Management), ISO 45001 (Occupational Health & Safety), and ISO 27001 (Information Security Management), reinforcing its commitment to delivering consistent, high-quality, safe and sustainable services worldwide. These certifications are standard across SK tes' global network of facilities and form a core part of the company's operating model. As the newest site within this network, Ireland's certification reflects the structured commissioning process that ensures every SK tes location meets the same rigorous international standards - enabling clients to receive a consistent, secure, and compliant service experience, regardless of geography. In parallel, the Irish business has been recognized in the DII Economic Report 2026, published by Digi
Preservica takes AI for Digital Preservation to the next level with powerful new AI Editions4.6.2026 15:00:00 CEST | Press release
OXFORD, UK AND BOSTON, MA / ACCESS Newswire / June 4, 2026 / Preservica, a global leader in AI-powered Active Digital Preservation™, today announced the launch of its new AI Editions that combine human-centric AI tools with the built-in AI capacity to enable archival and records teams to quickly and safely transform their archives at scale. Developed in collaboration with the Preservica user community, the new AI Editions enable teams to process backlogs up to four times faster, meet privacy, accessibility, and FOI requirements, standardize metadata quality, accelerate content enrichment and discovery, and free time for higher-value work. With ample AI capacity included, teams can save significant time - cutting repetitive, manual work and quickly adding new value to their archives every month: Transcribe hundreds of hours of AV content or OCR thousands of scanned images or Identify PII in hundreds of thousands of documents or Standardize metadata across thousands of assets And more "S
Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 20264.6.2026 14:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / June 4, 2026 / The Biotechnology Business Unit of Gedeon Richter Plc. (Richter) is present at this year's European Alliance of Associations for Rheumatology's (EULAR) European Congress of Rheumatology, underlining its role as a growing contributor to biologic therapies in Europe. The company also hosted a satellite symposium on the opening day, as part of its engagement with the rheumatology community. Richter's presence at EULAR reflects nearly two decades of focused investment following its strategic entry into biotechnology. Today, it operates a fully integrated biosimilars business with a European development and manufacturing network, including facilities in Budapest and Debrecen in Hungary, operations in Germany, and global partnerships supported by over 1,000 biotech professionals. As part of its scientific program, yesterday Richter hosted the symposium "Prevention, better than treatment - insights on inflammatory joint disease and osteoporosis" c
Media Invitation: Fields Medals and Cutting-Edge Math at ICM 2026 in Philadelphia2.6.2026 20:30:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / June 2, 2026 / Members of the press are invited to the world's most prestigious mathematics conference, which will take place at the Pennsylvania Convention Center in Philadelphia from July 23 to July 30, 2026. Held every four years, the International Congress of Mathematicians (ICM) includes the announcement of the field's top prizes - including the Fields Medals - as well as top talks from leading mathematicians on cutting-edge developments in the field. Staff reporters and freelance journalists can register to attend the conference free of charge through June 22. Media registration includes access to a press conference with the Fields Medalists and other honorees following their announcement during the July 23 opening ceremony. A press room will also be available during the conference. Discounted hotel room rates are available to attendees. For more information, visit the ICM 2026 website or email icmpressinquiries@simonsfoundation.org. The confe
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 06:00:00 CEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom